B
Bull
Bull · 25%SLRX
$0.73
シナリオ価格
$0.840
+0.246 (+29.23%)終値時点
Loading chart…
- High
- 0.898
- Open
- 0.706
- VWAP
- 0.81
- Vol
- 6.05M
- Mkt Cap
- 1.46M
- Low
- 0.686
- Amount
- 4.88M
- EV/EBITDA, TTM
- 0.02
Decoy Therapeutics Inc., formerly Salarius Pharmaceuticals, Inc., is a preclinical-stage biotechnology company that is leveraging machine learning and artificial intelligence (AI) tools alongside high-speed synthesis techniques to design, engineer and manufacture peptide conjugate drug candidates that target serious unmet medical needs. The Company’s initial pipeline is focused on respiratory viruses and GI cancers. In parallel, the Company is advancing discovery programs, including multi-virus decoy candidates designed to address overlapping respiratory threats, and cell-based and organoid-level validation of novel G protein-coupled receptor (GPCR)-targeted drug candidates outside of antivirals.
バリュエーション指標
The current forward P/E ratio for Salarius Pharmaceuticals Inc (SLRX) is -0.00, compared to its 5-year average forward P/E of -0.40.
Alphio AI Price Scenarios for SLRX
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
イベントタイムライン
ニュース
5.001-05BenzingaGH Research PLC Shares Surge 18.1% on FDA IND Status Update Announcement
9.012-19NewsfilterSalarius Pharmaceuticals Adjourns Annual Meeting to December 31 Due to Insufficient Votes
9.012-19GlobenewswireSalarius Pharmaceuticals Adjourns Annual Meeting to December 31, 2025 for Additional Votes
3.512-01GlobenewswireSalarius Partners with Texas Biomed to Develop Influenza Inhibitors
- 8.511-19Newsfilter
Salarius Pharmaceuticals Points Out Mistakes on S&P CapIQ Platform After Merging with Decoy Therapeutics, Confirms Its Shares Remain Listed on Nasdaq Under the Symbol "SLRX"
SLRX FAQ — answered by Alphio AI
Decoy Therapeutics Inc., formerly Salarius Pharmaceuticals, Inc., is a preclinical-stage biotechnology company that is leveraging machine learning and artificial intelligence (AI) tools alongside high-speed synthesis techniques to design, engineer and manufacture peptide conjugate drug candidates that target serious unmet medical needs. The Company’s initial pipeline is focused on respiratory viruses and GI cancers. In parallel, the Company is advancing discovery programs, including multi-virus decoy candidates designed to address overlapping respiratory threats, and cell-based and organoid-level validation of novel G protein-coupled receptor (GPCR)-targeted drug candidates outside of antivirals. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。